Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23008459 | 0.93 | — | — | |
| SCHEMBL24424824 | 0.85 | CA12 (0.44) | CA12CA2CA3CA4CA6 | |
| SCHEMBL24498684 | 0.84 | KDM5A (0.32) | — | |
| SCHEMBL24477267 | 0.84 | KDM5A (0.36) | — | |
| SCHEMBL15853595 | 0.82 | CHRM2 (0.37) | — | |
| SCHEMBL24515159 | 0.82 | KDM4E (0.37) | CA12CA2CA3CA4CA6 | |
| SCHEMBL8909834 | 0.82 | MEN1 (0.35) | — | |
| SCHEMBL19103231 | 0.81 | CA12 (0.36) | CA12CA2CA3CA4CA6 | |
| SCHEMBL24245892 | 0.80 | — | — | |
| SCHEMBL26434632 | 0.80 | PRMT3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150793-A9 | INHIBITORS OF MALIC ENZYME 1 | CORNELL UNIVERSITY (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023150793-A1 | INHIBITORS OF MALIC ENZYME 1 | CORNELL UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4105207-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-20210388196-A1 | GENE DELIVERY CARRIER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| WO-2019025488-A1 | REMOVAL OF BACTERIA FROM DRINKING WATER VIA FILTRATION | INSTRACTION GMBH (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2018098288-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-2831067-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017040271-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
| US-7323482-B2 | Thiazolyl-based compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070093537-A1 | Thiazolyl-based compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | GHRHR, GHITM, GHSR | CA12 3487/4885CA2 4797/4885CA3 4750/4885 |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | CD47, FCGR2A, CD40 | CA12 336/4885CA2 1923/4885CA3 2754/4885 |
| US-20210388196-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | CA12 1869/4885CA2 2925/4885CA3 3483/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | CA12 4661/4885CA2 3560/4885CA3 1936/4885 |
| US-20070093537-A1 | Thiazolyl-based compounds useful as kinase inhibitors | MAP3K1, MAPK1, MAP3K5 | CA12 4863/4885CA2 2407/4885CA3 4644/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | CA12 3503/4885CA2 3908/4885CA3 4505/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | CA12 3101/4885CA2 3625/4885CA3 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.